CareDx Health (CDNA): Price-to-Projected Revenue Ratio

CareDx, Inc (CDNA) revenues rely on clinic demand for transplant monitoring and insurance reimbursements. Operational efficiency is based on the ultra-fast transportation of biomaterials to laboratories. The specifics of diagnostics make the business resilient to any economic crises. The trajectory of the forward P/S helps assess market expectations, while the 13.30 level captures the current state of the multiple on the chart.

CareDx - CDNA Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

CareDx Health - analytical breakdowns and key metrics (CDNA)

- current price and projected stock value:

Stock Price CareDx Inc|CDNA - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value CareDx Health|CDNA - Value Adjusted for Debt and Cash

- book value of equity indicators:

Book Value per Share CareDx|CDNA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio caredx.com|CDNA - Total Business Assets

- debt and solvency information:

- financial results and valuation multiples details:

CDNA - Net Income|Projected Future Earnings CareDx, Inc|CDNA - Price to Earnings Ratio|Forward P/E Multiple CareDx, Inc.|CDNA - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CareDx Health|CDNA - Operating profit before amortization|Net earnings per share (EPS TTM) CareDx|CDNA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months caredx.com|CDNA - Net earnings per share growth this year|Earnings growth forecast for next year CareDx, Inc

- revenue and sales details:

CDNA - Company Total Revenue|Projected Sales Volume CareDx Health|CDNA - Market Cap to Revenue Ratio|Forward P/S Multiple CareDx Health

Summary company analysis:CareDx CDNA

CareDx, Inc (CDNA) monetizes high-tech transplant monitoring through genomic analysis of organ rejection risks. The expected volume of these sales correlates with the current market capitalization, forming a forward P/S ratio. This metric determines the extent of the premium paid for future cash flows, excluding the impact of short-term market volatility. By analyzing the trend of the forward P/S, an investor can assess the fairness of the market premium relative to the expansion rates of the diagnostic business.

Analysis of competing companies

Forward P/S Multiple A (Agilent)|Forward P/S Multiple Quest Diagnostics Inc. DGX|ILMN - Price-to-Projected Revenue Ratio|Forward Price to Sales EXAS (Exact Sciences Inc.)|RVTY: Forward P/S Multiple|Market Cap to Future Revenue Ratio bio-rad.com (BIO)|NNNN (Anbio) - Forward P/S Multiple|Market Cap to Projected Revenue SHC (Sotera Health Corp)|Forward Price-to-Revenue Multiple QDEL (QuidelOrtho Corp)|OPKO Health Corp. - Market Cap to Projected Revenue|Maravai LifeSciences - Forward Price-to-Revenue Multiple|Forward Price to Sales FLGT|Standard BioTools - Forward P/S Multiple|Market Cap to Expected Sales Ratio Cytek Biosciences Inc CTKB|OraSure Technologies Inc (OSUR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XGN|MDXH (MDxHealth SA) - Forward P/S Multiple|Forward Price-to-Revenue Multiple luciddx.com (LUCD)|Forward P/S Multiple PRE|Forward Price-to-Revenue Multiple imdxinc.com IMDX|Forward P/S Multiple TRIB (Trinity Biotech)|PRPH: Market Cap to Projected Revenue|AIMD - Price-to-Projected Revenue Ratio|CODX (codiagnostics.com) - Market Cap to Projected Revenue|HSCS: Forward P/S Multiple|Biomerica Inc. (BMRA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cardio Diagnostics Holdings Inc.|Forward Price-to-Revenue Multiple Onconetix Corporation (ONCO)|Forward P/S Multiple VRAX|BJDX - Market Cap to Future Revenue Ratio|Forward P/S Multiple AWH (Aspira Women's Health Inc.)|AXDX: Market Cap to Projected Revenue|centogene.com - Forward P/S Multiple|ENZ - Forward P/S Multiple|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue GENE|ME (23andMe) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Corp.